2nd Quarter - Amendment

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Firm
Client
Income
—
Expenses
$510,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 16, 2025 $450,000 Replaced
2nd Quarter - Amendment (this page) Oct 17, 2025 $510,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule; laboratory test coding, pricing, coverage, and payment; implementation of the Protecting Access to Medicare Act (P.L. 113-93); diagnostic regulatory reform; artificial intelligence in laboratory services; utilization management, including prior authorization policies impacting clinical laboratories.

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
SUSAN VAN METER —
MARY LEE WATTS —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule; laboratory test coding, pricing, coverage, and payment; implementation of the Protecting Access to Medicare Act (P.L. 113-93).

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
SUSAN VAN METER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule; laboratory test coding, pricing, coverage, and payment; implementation of the Protecting Access to Medicare Act (P.L. 113-93); diagnostics regulatory reform; FDA and CMS policies related to diagnostics and laboratory regulation; price transparency requirements for clinical laboratory services.

LobbyistCovered position, as disclosed
HOLLY GROSHOLZ —
SUSAN VAN METER —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.